Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Zacks Research

Keros Therapeutics (NASDAQ:KROS) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Wednesday,Zacks.com reports.

KROS has been the topic of several other research reports. Weiss Ratings downgraded shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.40.

Keros Therapeutics Stock Performance

Shares of Keros Therapeutics stock opened at $10.22 on Wednesday. The stock has a market capitalization of $202.27 million, a PE ratio of -3.40 and a beta of 0.97. Keros Therapeutics has a 52 week low of $9.69 and a 52 week high of $22.55. The stock has a 50 day moving average price of $10.73 and a two-hundred day moving average price of $12.72.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The firm had revenue of $0.37 million for the quarter, compared to analyst estimates of $1.93 million. Research analysts forecast that Keros Therapeutics will post -5.19 EPS for the current year.

Insider Activity

In related news, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director directly owned 10,958 shares of the company’s stock, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,425 shares of company stock valued at $89,994 over the last quarter. Company insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KROS. Renaissance Technologies LLC lifted its holdings in Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after purchasing an additional 436,986 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Keros Therapeutics during the 2nd quarter valued at $4,251,000. Caption Management LLC increased its holdings in shares of Keros Therapeutics by 114.1% in the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after purchasing an additional 291,997 shares during the period. Qube Research & Technologies Ltd increased its holdings in shares of Keros Therapeutics by 683.7% in the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after purchasing an additional 264,445 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock worth $3,547,000 after buying an additional 263,347 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.